Neumora Therapeutics Inc. (NMRA) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
490 ARSENAL WAY, SUITE 200 WATERTOWN, MA 02472 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 9/30/2024 MRQ | 12/31/2023 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 453,982,000 | |||
| Cash and cash equivalents | 374,038,000 | |||
| Short-term investments | 79,944,000 | |||
| Restricted cash and investments | ||||
| Receivables | 939,000 | |||
| Prepaid expense | 4,273,000 | |||
| Other undisclosed current assets | 19,085,000 | |||
| Total current assets: | 478,279,000 | |||
| Noncurrent Assets | ||||
| Operating lease, right-of-use asset | 5,068,000 | |||
| Property, plant and equipment | 1,790,000 | |||
| Long-term investments and receivables | 9,845,000 | |||
| Long-term investments | 9,845,000 | |||
| Restricted cash and investments | 1,213,000 | |||
| Total noncurrent assets: | 17,916,000 | |||
| TOTAL ASSETS: | 496,195,000 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 21,594,000 | |||
| Accounts payable | 337,000 | |||
| Accrued liabilities | 21,257,000 | |||
| Other undisclosed current liabilities | 3,517,000 | |||
| Total current liabilities: | 25,111,000 | |||
| Noncurrent Liabilities | ||||
| Liabilities, other than long-term debt | 1,853,000 | |||
| Operating lease, liability | 1,853,000 | |||
| Other undisclosed noncurrent liabilities | 155,000 | |||
| Total noncurrent liabilities: | 2,008,000 | |||
| Total liabilities: | 27,119,000 | |||
| Equity | ||||
| Equity, attributable to parent | 469,076,000 | |||
| Common stock | 16,000 | |||
| Additional paid in capital | 1,172,570,000 | |||
| Accumulated other comprehensive income (loss) | (76,000) | |||
| Accumulated deficit | (703,434,000) | |||
| Total equity: | 469,076,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 496,195,000 | |||
Income Statement (P&L) (USD)
| 9/30/2024 TTM | 12/31/2023 | ||
|---|---|---|---|
| Operating expenses | (252,098,000) | ||
| Operating loss: | (252,098,000) | ||
| Nonoperating income | 16,441,000 | ||
| Loss from continuing operations before income taxes: | (235,657,000) | ||
| Income tax expense | (268,000) | ||
| Other undisclosed loss from continuing operations | |||
| Net loss available to common stockholders, diluted: | (235,925,000) | ||
Comprehensive Income (USD)
| 9/30/2024 TTM | 12/31/2023 | ||
|---|---|---|---|
| Net loss: | (235,925,000) | ||
| Comprehensive loss: | (235,925,000) | ||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 698,000 | ||
| Comprehensive loss, net of tax, attributable to parent: | (235,227,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.